Related Experiment Video
Updated: May 11, 2026
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
Association of Plasma Brain-Derived Tau With Functional Outcome After Ischemic Stroke
Tara M Stanne1, Fernando Gonzalez-Ortiz1, Cecilia Brännmark1
1From the Department of Laboratory Medicine (T.M.S., C.B., C.J.), Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg; Department of Clinical Genetics and Genomics (T.M.S., C.J.), Region Västra Götaland, Sahlgrenska University Hospital; Department of Psychiatry and Neurochemistry (F.G.-O., T.K., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg; Clinical Neurochemistry Laboratory (F.G.-O., K.B.); Department of Research, Development, Education and Innovation (C.B.), Region Västra Götaland, Sahlgrenska University Hospital; Department of Clinical Neuroscience (K.J.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy, University of Gothenburg; Department of Neurology (K.J.), Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden; and Department of Psychiatry (T.K.), University of Pittsburgh.
Objectives:
To investigate whether circulating acute-phase brain-derived tau (BD-tau) is associated with functional outcome after ischemic stroke.
Methods:
Plasma tau was measured by a novel assay that selectively quantifies BD-tau in the Sahlgrenska Academy Study on Ischemic Stroke (SAHLSIS), which includes adult cases with ischemic stroke and controls younger than 70 years, and in an independent cohort of adult cases of all ages (SAHLSIS2). Associations with unfavorable 3-month functional outcome (modified Rankin scale score >2) were analyzed by logistic regression. Various stratified and sensitivity analyses were performed, for example, by age, stroke severity, recanalization therapy, and etiologic subtype.
Results:
This study included 454 and 364 cases from the SAHLSIS and SAHLSIS2, with a median age of 58 and 68 years, respectively. Higher acute BD-tau concentrations were significantly associated with increased odds of unfavorable outcome after adjustment for age, sex, day of blood draw, and stroke severity (NIH stroke scale score) in both cohorts (OR per doubling of BD-tau: 2.9 [95% CI 2.2-3.7], P = 1 × 10-15 and 1.8 [1.5-2.2], P = 7 × 10-9, respectively). The association was consistent in the different stratified and sensitivity analyses.
Discussion:
BD-tau is a promising blood-based biomarker of ischemic stroke outcomes, and future studies in larger cohorts are warranted.
More Related Videos
06:45Author Spotlight: Integrated Photoacoustic, Ultrasound, and Angiographic Tomography (PAUSAT) for NonInvasive Whole-Brain Imaging of Ischemic Stroke
Published on: June 2, 2023
11:32Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke
Published on: January 3, 2025
